CBIO Q2 2024 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$12,423

Operating Income

-$10M

Net Income

-$10M

EPS (Diluted)

$-0.16

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$24M

Total Liabilities

$4M

Stockholders' Equity

$20M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$12,423	-$265,866	+95.3%
Operating Income	-$10M	-$9M	-16.0%
Net Income	-$10M	-$8M	-22.2%